Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Important. The additional 8 million in cash lets AVXL negotiate higher prices for buyouts or partnerships since Missling repeated there is enough cash for 2 years without any further dilution ! Any weakness in sp imo will be bought. If 8 million was raised @ $4, thats only 2m shares but may led to 1-2 billion !
My educated guess is that the extra funds came from the remaining warrants being exercised. If you have been here awhile you would have known about them. They were probably exercised and are in the hands of long term holders or people close to the company on initial funding. These people may know what is coming soon !
AVXL just stabilized Alzheimers for a full year ! Homerun ! !
Open @ $18, close at $22+ tomorrow?
open @ $6 close at $8+ tomorrow?
AVXL stabilzes Alzheimers over 1 year and still going. CTAD Dec 2016.
page 24: P300 Amplitude recovers to healthy levels plus over 53 weeks !!!
Page 27: At 53 weeks, Anavex 2-73 blows away SOC in processing speed. attention, working memory, visual learning, verbal learning and verbal memory..WOW.in all categories.
Cramer just said be cautious in BIIB, stock is up a little on AD news but recommends caution.
falconer66a Thursday, 12/08/16 09:40:34 PM
Re: None
Post #
82688
of 82746 Go
Observations of a small retail AVXL shareholder.
I thank everyone for their postings on this board. Varying viewpoints and perspectives, to be carefully read and considered by those of us with an interest or position in Anavex.
I’m a field biologist and biology instructor, reasonably familiar with the cellular biochemistry of the neuron. None of what I relate here should be construed as investment advice or encouragement; merely the perspectives of an informed small-time retail AVXL investor.
First, I believe and understand that Anavex’s Alzheimer’s treatment approach is unique and wholly different from any drug on the market or under development by any other company. This sets Anavex apart. Its story and future are entirely different from those of any other drug development or sales company. Comparisons with existing Alzheimer’s treatment drugs, about a dozen, with only three or four in common usage, are invalid. None of these have been able to effectively stop or reverse Alzheimer’s symptoms. They merely slow disease progression for a period (often only for a few weeks or months).
As I interpret the available clinical data, Anavex 2-73, in fact, stops symptomatic progression, keeping the disease from progressing to ever more debilitating stages. Yes, the clinical population sizes from which these results are derived are small; but statistically significant, and consistent across the populations. I’m convinced that any future clinical trials of Anavex 2-73 will merely further substantiate the molecule’s unique biochemistry, restoring defective neurons to “homeostasis,” a normalized, fully functioning status. This is accomplished by 2-73's ability to re-connect dislodged or poorly-connected endoplasmic reticula to mitochondria. This restores normalized protein folding in the endoplasmic reticula, creating fully- and normally-functioning reaction-controlling enzymes. With those, neurons will operate healthfully.
All of that is crucial. Other Alzheimer’s drugs attempt to remove A-beta plaques, or tau-tangles, waste protein accumulations found in all Alzheimer’s-affected neurons (but also, incongruously, often in fully healthy people, too). Millions of research dollars have been spent in perfecting and testing waste protein removal drugs; with no success. Many pharmaceutical companies and neurologists persist in this evermore useless pursuit. Anavex has a much better, cheaper, and effective approach. Cause neurons to synthesize functioning enzymes by facilitating normalized endoplasmic reticulum-mitochondria connections.
Another crucial clinical finding. Anavex 2-73 easily crosses the blood-brain barrier, efficiently diffusing into neurons. Few other drugs do this. This allows minimal dosages, in posted clinical trials between 10 and 50 milligrams per day, administered orally (not by injection). Ease of administration, effective in low doses. Extremely useful.
Then, on top of all of this — and it is crucial for FDA approval — Anavex 2-73 has had few or no adverse events in the posted clinical trials. No disqualifying side effects. This is exceptionally rare for any drug or chemical acting inside nerves and neurons. Anavex 2-73 easily gets into neurons, re-connects disconnected endoplasmic reticula with their associated mitochondria, and the neuron then functions normally — without untoward results.
With an understanding all of this I’m convinced the Food and Drug Administration will sooner or later authorize widespread clinical use of Anavex 2-73, at least at the start, for this seminal reason: Anavex 2-73 exceeds any Standard of Care (SOC) results for any existing Alzheimer’s treatment drug. They merely slow for a time (at best) the progression of symptoms. Anavx 2-73 stops symptomatic progression; meaning that if administered at the start of (or before) symptoms, the disease can be chronically suppressed and the patient maintained in a normal mental state. Anavex will become the new Standard of Care drug for Alzheimer’s. No competition.
Eventually, I see widespread prophylactic (preventative) use of 2-73. It may eventually be commonly administered to virtually everyone at the age of 50 or 60, keeping Alzheimer’s from ever developing. No side effects. A small, cheap protein, easily administered.
And, for an expanded story, consider 2-73's eventual treatment or prevention of Parkinson’s disease and other geriatric neurodegenerative diseases. Animal tests indicate equivalent efficacies.
In fact, I suffer (not badly) from hereditary spastic paraplegia (HSP), where the motor neurons of my spine are hyperactive, causing adductor muscles in my thighs to remain tight. I walk with difficulty (but no pain). There is a French report where transgenic rats, with the inserted genetic defect of my disease, were treated with Anavex 2-73 and their spasticity was resolved. Yes, I’m hoping that can eventually happen with me.
I won’t elaborate on the expansive pipeline of other molecules Anavex owns and is developing for other diseases. If only Anavex 2-73 comes to market the company will be a giant success (especially for those of us with equity positions). But I think Anavex 2-73 is the subject of only a few of the early chapters in the eventually more gigantic Anavex story.
Abstracts appear to show AVXL results better than BIIB.
Will LLY buy AVXL after seeing their Alzheimers results or will it be BIIB?
Would not want to be short AVXL short term or long term. Too many potential suitors imo.
Big offers so shorts can cover before the conference? They are pretty transparant imo.
AREX... The value of all Permian acres regardless of location has increased much over past two years. What is the current value of AREX acres? $7,000, $10,000, $12,000 per acre ?
At 10k acre x 126k acres = 1.26 Billion less 500M debt = 726M to shareholders with 41.61 million current shares outstanding that would be $17.44 per share
$40+ less than 23 months ago and now only a 2 million float !
See AVXL work:
George Perry, PhD, Dean and Professor at the University of Texas at San Antonio and Editor-in Chief of the Journal of Alzheimer's Disease, commented, "Although this is an open label study with 32 patients, I have never seen mild-to-moderate Alzheimer's patients maintain near baseline cognitive and activities of daily living function and positive correlation with all other measures over a 41-week trial period in any prior study with an approved or experimental drug. It is quite plausible that complex CNS diseases like Alzheimer's may require a comprehensive approach, including restoration of cellular homeostasis."
Re: AVXL
George Perry, PhD, Dean and Professor at the University of Texas at San Antonio and Editor-in Chief of the Journal of Alzheimer's Disease, commented, "Although this is an open label study with 32 patients, I have never seen mild-to-moderate Alzheimer's patients maintain near baseline cognitive and activities of daily living function and positive correlation with all other measures over a 41-week trial period in any prior study with an approved or experimental drug. It is quite plausible that complex CNS diseases like Alzheimer's may require a comprehensive approach, including restoration of cellular homeostasis."
Will Meg Tirell at CNBC cover AVXL now? Maybe someone should send them some news on AVXL. Recent interviews with LLY say that no drug stabilizes AD. powerlunch@cnbc if interested.
Will LLY buy AVXL or will it be BIIB? BIIB already testing their drug in MS.
LLY drug fails so who will buy AVXL first, LLY or BIIB?
AVXL Alzheimer drug is working and BIIB already testing it in MS, Will BIIB let LLY buy AVXL?
SATURDAY, DECEMBER 10, 2016 8.45 a.m OC60 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1
, Marco Cecchi, PhD2
, Paul Maruff, PhD3
, Kristina M Kapiak4
, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,
USA
http://www.ctad-alzheimer.com/sites/ctad.prod/files/files/PROGRAMfinal_CTAD2016_8nov%20.pdf
Annual High is $111
So 12 month data is still to come at this meeting !!
Do your DD. They are very helpful at CTAD. They just updated their program.
Presentation moved from Friday to Saturday to be in front of more people, 1200 people according to CTAD. The friday presentation was initially in a split format during anothers presentation so Saturday was chosen by committee for full attendance.
Is AVXL presenting at CTAD on Dec 8-10? I see they are a silver sponsor.
Which poster is theirs?
CNBC talking genetics today. Look at SGNL.
Just announced, SINO posts .08 eps with small float !
Big news. SINO just posted .08/qrt eps !
Wow. SINO announces .08 eps quarter and with a low float could get huge !
Strongest shipper with .08 eps this quarter and low float is SINO.
Best shipper is SINO. They just posted .08 and small float.
SINO posts .08 earnings
News! SINO announces .08 eps and has a tiny float.
SINO with low float and announces .08 eps .
TOPS micro float 600k+ DRYS has 450K. All other shippers much higher floats.
DRYS and TOPS micro floats of 400k+ and 600k+